Dauntless 1 — An improved therapeutic for the treatment of endocrine cancers.
We are developing a therapeutic agent, DP1038, for the treatment of endocrine cancers in Dauntless 1. DP1038 will follow a 505(b)(2) pathway to speed development and reduce costs. DP1038 completed nonclinical toxicology studies in 2016 and will be evaluated in a Phase 1 first-in-human clinical trial in early 2017.
We are actively seeking additional drug candidates to expand our pipeline through the addition of new companies to the Dauntless Pharmaceuticals portfolio.